<code id='5E8B1C27EB'></code><style id='5E8B1C27EB'></style>
    • <acronym id='5E8B1C27EB'></acronym>
      <center id='5E8B1C27EB'><center id='5E8B1C27EB'><tfoot id='5E8B1C27EB'></tfoot></center><abbr id='5E8B1C27EB'><dir id='5E8B1C27EB'><tfoot id='5E8B1C27EB'></tfoot><noframes id='5E8B1C27EB'>

    • <optgroup id='5E8B1C27EB'><strike id='5E8B1C27EB'><sup id='5E8B1C27EB'></sup></strike><code id='5E8B1C27EB'></code></optgroup>
        1. <b id='5E8B1C27EB'><label id='5E8B1C27EB'><select id='5E8B1C27EB'><dt id='5E8B1C27EB'><span id='5E8B1C27EB'></span></dt></select></label></b><u id='5E8B1C27EB'></u>
          <i id='5E8B1C27EB'><strike id='5E8B1C27EB'><tt id='5E8B1C27EB'><pre id='5E8B1C27EB'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:focus    Page View:41847
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Breakthrough Alzheimer’s drugs are inaccessible in rural states
          Breakthrough Alzheimer’s drugs are inaccessible in rural states

          Libby,MontanaRickBowmer/APNewtreatmentsaredelayingtheprogressionofAlzheimer’sdisease,givingpeopleagi

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

          KristofferTripplaar/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiot